Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ken Garber

Showing results (21-30 of 194) with videos related to

Pageof 20
Sort By:
Nature Biotechnology|May 8, 2018
Cytokine resurrection: engineered IL-2 ramps up immuno-oncology responsesKen Garber
Nature Biotechnology|April 10, 2010
Biotech in a blinkKen Garber
Journal of the National Cancer Institute|March 27, 2010
Stromal depletion goes on trial in pancreatic cancerKen Garber
Nature Biotechnology|June 11, 2009
Ariad's NFkappaB patent claims shot down on appealKen Garber
Journal of the National Cancer Institute|January 1, 2009
From human to mouse and back: 'tumorgraft' models surge in popularityKen Garber
Nature Biotechnology|October 11, 2008
Fixing the front endKen Garber
Journal of the National Cancer Institute|July 9, 2009
JAK2 inhibitors: not the next imatinib but researchers see other possibilitiesKen Garber
Journal of the National Cancer Institute|August 13, 2009
First results for agents targeting cancer-related inflammationKen Garber
Science (New York, N.Y.)|June 30, 2018
Blood test may predict cancer immunotherapy benefitKen Garber
Nature Biotechnology|August 9, 2008
Infections cast cloud over Novartis' MS therapyKen Garber
Pageof 20

Showing results (21-30 of 194) with videos related to

Sort By:
Pageof 20
Nature Biotechnology|May 8, 2018
Cytokine resurrection: engineered IL-2 ramps up immuno-oncology responsesKen Garber
Nature Biotechnology|April 10, 2010
Biotech in a blinkKen Garber
Journal of the National Cancer Institute|March 27, 2010
Stromal depletion goes on trial in pancreatic cancerKen Garber
Nature Biotechnology|June 11, 2009
Ariad's NFkappaB patent claims shot down on appealKen Garber
Journal of the National Cancer Institute|January 1, 2009
From human to mouse and back: 'tumorgraft' models surge in popularityKen Garber
Nature Biotechnology|October 11, 2008
Fixing the front endKen Garber
Journal of the National Cancer Institute|July 9, 2009
JAK2 inhibitors: not the next imatinib but researchers see other possibilitiesKen Garber
Journal of the National Cancer Institute|August 13, 2009
First results for agents targeting cancer-related inflammationKen Garber
Science (New York, N.Y.)|June 30, 2018
Blood test may predict cancer immunotherapy benefitKen Garber
Nature Biotechnology|August 9, 2008
Infections cast cloud over Novartis' MS therapyKen Garber
Pageof 20